Tarveda Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

About Tarveda Therapeutics

Tarveda Therapeutics, Inc., is a biopharmaceutical company discovering and developing Pentarins™ as a new class of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized biologic drug conjugate that targets the somatostatin receptor for neuroendocrine cancers including small cell lung cancer. Tarveda’s strategy includes developing its own proprietary Pentarins as well as collaborating with industry partners to enhance the effectiveness of targeting protein scaffolds and payloads by creating novel Pentarins. Tarveda has attracted top-tier investors including Novo A/S, New Enterprise Associates, Flagship Ventures, NanoDimension, and Eminent Venture Capital. For more information, visit www.tarveda.com.

Contacts

The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com